Annexin A2 as immunological target
AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.
1. A method of treating a patient with pancreatic ductal adenocarcinoma comprising:
subjecting the patient to radiotherapy and/or chemotherapy;
measuring expression of AnnexinA2 whose tyrosine 23 residue is phosphorylated on pancreatic ductal adenocarcinoma tumor cells of the patient using an anti-AnnexinA2 antibody and an anti-phosphotyrosine antibody;
administering to the patient identified as expressing the AnnexinA2, a monoclonal antibody which specifically binds to a form of AnnexinA2 whose tyrosine 23 residue is phosphorylated, and
diminishing risk of tumor invasion and metastatic progression, thereby treating a patient with pancreatic ductal adenocarcinoma.
2. The method of claim 1 , wherein the radiotherapy and/or chemotherapy is administered prior to and/or concomitantly with the administration of the monoclonal antibody specific for the AnnexinA2.
3. The method of claim 2 , wherein the radiotherapy and/or chemotherapy is administered prior to administration of the monoclonal antibody specific for the AnnexinA2.
4. The method of claim 1 , further comprising resecting the tumor.
5. A method of treating a patient with pancreatic ductal adenocarcinoma comprising:
measuring expression of AnnexinA2 having a phosphorylated tyrosine 23 residue on pancreatic ductal adenocarcinoma tumor cells of the patient using an anti-AnnexinA2 antibody and an anti-phosphotyrosine antibody;
administering to the patient identified as expressing AnnexinA2 having a phosphorylated tyrosine 23 residue, a pharmaceutical composition comprising a monoclonal antibody which specifically binds AnnexinA2, in an amount effective to diminish risk of tumor invasion and metastatic progression, thereby treating a patient with pancreatic ductal adenocarcinoma.
6. The method of claim 5 , wherein the method of treatment further comprises an additional step of administering to the patient radiotherapy, chemotherapy and/or tumor resection.